Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin (Canadian Cancer Trials Group)
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + cisplatin is a combination chemotherapy regimen that was evaluated by the NCIC Clinical Trials Group (now the Canadian Cancer Trials Group) in a Phase II clinical trial for patients with advanced, metastatic, or locoregionally recurrent malignant salivary gland tumors. Gemcitabine is a nucleoside analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase and competing with cytidine for incorporation into DNA. Cisplatin (or its analog carboplatin, used in patients with contraindications to cisplatin) is a platinum-based antineoplastic agent that forms covalent DNA cross-links, leading to DNA damage and apoptosis. The trial (NCIC CTG HN.4) demonstrated an objective response rate of 24%, which did not meet the predefined efficacy criteria to warrant further investigation in this specific indication.
- Other names
- gemcitabine + carboplatinGemCisGC regimen
02
Targets
DNA polymerase familyRNR (Ribonucleotide reductase)POLG (Mitochondrial DNA polymerase gamma)POLRMT (Mitochondrial RNA polymerase)DNA
Beyond the preview
Go deeper on gemcitabine + cisplatin (Canadian Cancer Trials Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin (Canadian Cancer Trials Group).